Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 0 | $0 |
| Sells | 158 | $89,080,546 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 14 Mar 2024 16:17 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 13 Mar 2024 | Sale | 3,452 | 58.1335 | 200,677 | D |
| 14 Mar 2024 16:17 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 13 Mar 2024 | Sale | 7,768 | 57.307 | 445,161 | D |
| 11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 100 | 63.35 | 6,335 | D |
| 11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 26,257 | 62.6896 | 1,646,041 | D |
| 11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 42,750 | 61.8754 | 2,645,173 | D |
| 05 Mar 2024 16:04 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Mar 2024 | Sale | 2,000 | 63.95 | 127,900 | D |
| 05 Mar 2024 16:04 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Mar 2024 | Sale | 4,000 | 62.86 | 251,440 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 413 | 65.68 | 27,126 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 116,512 | 64.9163 | 7,563,528 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 41,704 | 62.9631 | 2,625,813 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 62,503 | 64.2573 | 4,016,274 | D |
| 05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 28,868 | 62.213 | 1,795,965 | D |
| 13 Feb 2024 17:05 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 12 Feb 2024 | Sale | 1,148 | 67.7669 | 77,796 | D |
| 13 Feb 2024 17:06 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 12 Feb 2024 | Sale | 781 | 67.7669 | 52,926 | D |
| 13 Feb 2024 16:59 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 12 Feb 2024 | Sale | 1,431 | 67.7669 | 96,974 | D |
| 13 Feb 2024 16:49 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 12 Feb 2024 | Sale | 3,962 | 67.7669 | 268,492 | D |
| 13 Feb 2024 16:43 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 12 Feb 2024 | Sale | 1,148 | 67.7669 | 77,796 | D |
| 13 Feb 2024 16:38 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 12 Feb 2024 | Sale | 597 | 67.7669 | 40,457 | D |
| 31 Jan 2024 16:36 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
| 31 Jan 2024 16:38 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
| 31 Jan 2024 16:31 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 29 Jan 2024 | Sale | 835 | 64.1382 | 53,555 | D |
| 31 Jan 2024 16:34 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
| 31 Jan 2024 16:26 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 29 Jan 2024 | Sale | 2,843 | 64.1382 | 182,345 | D |
| 31 Jan 2024 16:28 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 30 Jan 2024 | Sale | 883 | 65.53 | 57,863 | D |
| 31 Jan 2024 16:28 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 29 Jan 2024 | Sale | 367 | 64.1382 | 23,539 | D |
| 31 Jan 2024 16:21 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 29 Jan 2024 | Sale | 874 | 64.1382 | 56,057 | D |
| 31 Jan 2024 16:23 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 29 Jan 2024 | Sale | 279 | 64.1382 | 17,895 | D |
| 31 Jan 2024 16:23 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 30 Jan 2024 | Sale | 971 | 65.53 | 63,630 | D |
| 31 Jan 2024 16:18 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 29 Jan 2024 | Sale | 367 | 64.1382 | 23,539 | D |
| 24 Jan 2024 16:06 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 23 Jan 2024 | Sale | 4,286 | 63.69 | 272,975 | D |
| 24 Jan 2024 16:03 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 23 Jan 2024 | Sale | 7,378 | 63.69 | 469,905 | D |
| 23 Jan 2024 19:28 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 22 Jan 2024 | Sale | 13,431 | 64.996 | 872,961 | D |
| 23 Jan 2024 18:15 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 22 Jan 2024 | Sale | 3,413 | 64.996 | 221,831 | D |
| 23 Jan 2024 18:17 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 22 Jan 2024 | Sale | 4,184 | 64.996 | 271,943 | D |
| 23 Jan 2024 18:11 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 22 Jan 2024 | Sale | 2,593 | 64.996 | 168,535 | D |
| 23 Jan 2024 18:13 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 22 Jan 2024 | Sale | 3,551 | 64.996 | 230,801 | D |
| 23 Jan 2024 18:05 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 22 Jan 2024 | Sale | 1,607 | 64.996 | 104,449 | D |
| 23 Jan 2024 18:07 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 22 Jan 2024 | Sale | 1,738 | 64.996 | 112,963 | D |
| 23 Jan 2024 18:00 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 22 Jan 2024 | Sale | 1,061 | 64.996 | 68,961 | D |
| 23 Jan 2024 18:01 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 22 Jan 2024 | Sale | 1,384 | 64.996 | 89,954 | D |
| 23 Jan 2024 18:03 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 22 Jan 2024 | Sale | 3,913 | 64.996 | 254,329 | D |
| 18 Jan 2024 16:55 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 17 Jan 2024 | Sale | 5,207 | 65.58 | 341,475 | D |
| 18 Jan 2024 16:54 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 17 Jan 2024 | Sale | 3,276 | 65.58 | 214,840 | D |
| 17 Jan 2024 16:45 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 16 Jan 2024 | Sale | 864 | 66.8086 | 57,723 | D |
| 17 Jan 2024 16:47 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 16 Jan 2024 | Sale | 1,632 | 66.8086 | 109,032 | D |
| 17 Jan 2024 16:40 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 16 Jan 2024 | Sale | 1,857 | 66.8086 | 124,064 | D |
| 17 Jan 2024 16:41 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 16 Jan 2024 | Sale | 1,631 | 66.8086 | 108,965 | D |
| 17 Jan 2024 16:43 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 16 Jan 2024 | Sale | 1,632 | 66.8086 | 109,032 | D |
| 17 Jan 2024 16:36 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 16 Jan 2024 | Sale | 2,235 | 66.8086 | 149,317 | D |
| 17 Jan 2024 16:37 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 16 Jan 2024 | Sale | 2,235 | 66.8086 | 149,317 | D |
| 17 Jan 2024 16:38 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 16 Jan 2024 | Sale | 4,240 | 66.8086 | 283,268 | D |
| 17 Jan 2024 16:32 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 Jan 2024 | Sale | 7,851 | 66.8086 | 524,514 | D |
| 17 Jan 2024 12:24 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 16 Jan 2024 | Sale | 438 | 66.8086 | 29,262 | D |
| 05 Jan 2024 16:14 | APLS | Apellis Pharmaceuticals Inc | BAUMAL CAROLINE | Chief Medical Officer | 04 Jan 2024 | Sale | 2,751 | 60.0534 | 165,207 | D |
| 28 Dec 2023 16:13 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 27 Dec 2023 | Sale | 235 | 60.23 | 14,154 | D |
| 28 Dec 2023 16:13 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 26 Dec 2023 | Sale | 68 | 57.8609 | 3,935 | D |
| 20 Dec 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 19 Dec 2023 | Sale | 2,300 | 57.3827 | 131,980 | D |
| 20 Dec 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 19 Dec 2023 | Sale | 1,605 | 57.0041 | 91,492 | D |
| 05 Dec 2023 19:40 | APLS | Apellis Pharmaceuticals Inc | SCHEIBLER LUKAS | Chief Research Officer | 01 Dec 2023 | Sale | 10,000 | 60 | 600,000 | D |
| 05 Dec 2023 19:29 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 01 Dec 2023 | Sale | 67,557 | 60.5019 | 4,087,327 | D |
| 05 Dec 2023 19:29 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 01 Dec 2023 | Sale | 42,443 | 61.3052 | 2,601,977 | D |
| 05 Dec 2023 16:21 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 01 Dec 2023 | Sale | 24,000 | 61.135 | 1,467,240 | I |
| 01 Dec 2023 16:11 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 30 Nov 2023 | Sale | 300 | 54.7866 | 16,436 | D |
| 01 Dec 2023 16:11 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 30 Nov 2023 | Sale | 13,858 | 54.73 | 758,448 | D |
| 21 Nov 2023 17:36 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 21 Nov 2023 | Sale | 5,000 | 48.8 | 244,000 | D |
| 21 Nov 2023 16:36 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 17 Nov 2023 | Sale | 8,894 | 49.991 | 444,620 | D |
| 21 Nov 2023 16:00 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 17 Oct 2023 | Sale | 24,000 | 49 | 1,176,000 | I |
| 20 Nov 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Nov 2023 | Sale | 1,250 | 47.74 | 59,675 | D |
| 09 Nov 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Nov 2023 | Sale | 12,000 | 47.27 | 567,240 | D |
| 24 Oct 2023 16:20 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 23 Oct 2023 | Sale | 132 | 46.0362 | 6,077 | D |
| 24 Oct 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 23 Oct 2023 | Sale | 131 | 46.0362 | 6,031 | D |
| 18 Oct 2023 17:43 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Oct 2023 | Sale | 1,250 | 48.5 | 60,625 | D |
| 10 Oct 2023 16:26 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 09 Oct 2023 | Sale | 12,000 | 40.38 | 484,560 | D |
| 19 Sep 2023 17:05 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 18 Sep 2023 | Sale | 1,250 | 45 | 56,250 | D |
| 19 Sep 2023 17:03 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 18 Sep 2023 | Sale | 10,631 | 46.147 | 490,589 | D |
| 19 Sep 2023 17:03 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 18 Sep 2023 | Sale | 9,719 | 42.2085 | 410,224 | D |
| 18 Sep 2023 16:24 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 15 Sep 2023 | Sale | 1,250 | 45.34 | 56,675 | D |
| 11 Sep 2023 16:58 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Sep 2023 | Sale | 12,000 | 42.87 | 514,440 | D |
| 07 Sep 2023 16:08 | APLS | Apellis Pharmaceuticals Inc | SCHEIBLER LUKAS | Chief Research Officer | 06 Sep 2023 | Sale | 1,756 | 43.01 | 75,526 | D |
| 17 Sep 2024 17:21 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 16 Sep 2024 | Sale | 7,524 | 36.79 | 276,808 | I |
| 17 Sep 2024 17:21 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 16 Sep 2024 | Sale | 29,476 | 36.09 | 1,063,789 | I |
| 17 Sep 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 16 Sep 2024 | Sale | 192 | 36.206 | 6,952 | D |
| 04 Sep 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 03 Sep 2024 | Sale | 550 | 39.491 | 21,720 | D |
| 21 Jun 2024 19:34 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 21 Jun 2024 | Sale | 1,695 | 39.63 | 67,173 | I |
| 21 Jun 2024 19:34 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 21 Jun 2024 | Sale | 35,305 | 39.22 | 1,384,662 | I |
| 09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 100 | 44.025 | 4,402 | D |
| 09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 22,472 | 42.849 | 962,903 | D |
| 09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 56,335 | 42.1504 | 2,374,543 | D |
| 09 Apr 2024 16:25 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Apr 2024 | Sale | 4,728 | 54.9152 | 259,639 | D |
| 09 Apr 2024 16:25 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Apr 2024 | Sale | 64,379 | 54.1165 | 3,483,966 | D |
| 02 Apr 2024 16:06 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Apr 2024 | Sale | 4,000 | 58.66 | 234,640 | D |
| 20 Mar 2024 17:18 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 19 Mar 2024 | Sale | 18,681 | 57.179 | 1,068,161 | I |
| 19 Mar 2024 16:03 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 18 Mar 2024 | Sale | 9,913 | 56.9 | 564,050 | D |
| 18 Mar 2024 16:19 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 15 Mar 2024 | Sale | 184 | 56.461 | 10,389 | D |
| 01 Sep 2023 16:05 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Sep 2023 | Sale | 10,284 | 42.44 | 436,453 | D |
| 01 Sep 2023 16:05 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Sep 2023 | Sale | 139,716 | 41.7025 | 5,826,506 | D |
| 01 Sep 2023 16:08 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 31 Aug 2023 | Sale | 551 | 41.226 | 22,716 | D |
| 09 Aug 2023 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Aug 2023 | Sale | 12,000 | 23.66 | 283,920 | D |
| 18 Jul 2023 16:40 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Jul 2023 | Sale | 1,250 | 64.79 | 80,988 | D |
| 11 Jul 2023 17:37 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 10 Jul 2023 | Sale | 12,000 | 84.55 | 1,014,600 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)